MedPage Today1d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
FDA keeps Mounjaro off shortage list after reevaluation
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...
FiercePharma2d
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
BioPharma Dive2d
Zepbound, Mounjaro shortages are resolved, FDA confirms
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
The National Law Review1d
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...
What is Mounjaro? The Ozempic-style weight-loss drug being rolled out on the NHS
They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...
Healthline6d
Where to Buy Mounjaro Online Safely in 2025: Advice from Our Experts
See which services passed our rigorous vetting process. Share on Pinterest Mounjaro (tirzepatide) is an injectable medication that’s approved for diabetes by the Food and Drug Administration (FDA) ...
PharmiWeb4d
Best Mounjaro Alternative Over the Counter: Cheaper, Safer Alternatives to Tirzepatide OTC
If you are considering a natural over the counter Mounjaro alternative for 2025 - we have the top 3 options for you. However, Mounjaro isn't the right fit for everyone. Since it's a prescription ...
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.